Browsing Tag

Chemoradiation

Apexigen Presents New Data from a Phase 2 Trial Evaluating its CD40 Antibody,…

Eli Pacheco Sep 10, 2022 0

SAN CARLOS, Calif., Sept. 10, 2022 (GLOBE NEWSWIRE) -- Apexigen, Inc. (NASDAQ: APGN) a clinical-stage company focused on developing innovative antibody-based therapeutics for the…

Health

Apexigen Announces New Data from a Phase 2 Trial Evaluating its CD40 Antibody,…

Eli Pacheco Sep 5, 2022 0

SAN CARLOS, Calif., Sept. 05, 2022 (GLOBE NEWSWIRE) -- Apexigen, Inc. (NASDAQ: APGN) a clinical-stage company focused on developing innovative antibody-based therapeutics for the…

Health

OncXerna Therapeutics Announces Upcoming ASCO Poster Featuring Data Showing the Phase…

Eli Pacheco Jun 4, 2022 0

Trial’s 73% twelve-month overall survival rate in newly diagnosed glioblastoma patients compares favorably to historical benchmark of 60% Results show median progression-free survival of…